EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Improved tendon repair with optimized chemically modified mRNAs: Combined delivery of Pdgf-BB and IL-1Ra using injectable nanoparticles

Bettina Faustini, Thomas Lettner, Andrea Wagner, Herbert Tempfer, Nevra Pelin Cesur, Christine Lehner, Chantal Brouwer, Karin Roelofs, Olga Mykhailyk, Christian Plank, Jaap Rip, Renate Gehwolf und 1 weitere

Acta Biomaterialia · 2025-03 · 195 · 451-466

DOI: 10.1016/j.actbio.2025.02.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2025-03. Verfasst von Bettina Faustini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Tendon and Bone Regeneration, Paracelsus Medical University, 5020 Salzburg, Austria; Department of Biosciences and Medical Biology, Univ…. Hauptthemen laut MEDLINE: Nanoparticles, RNA, Messenger, Becaplermin, Interleukin 1 Receptor Antagonist Protein. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eurostars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tendon injuries, common in both athletic and non-athletic populations, present significant challenges due to their slow healing and the formation of scar tissue, which impairs function and potentially increases the risk of (re-)rupture. Conventional treatments often yield suboptimal functional and structural repair. This study investigates the potential of mRNA-based therapeutics to enhance tendon healing by targeting 2 distinct pathways via the delivery of chemically modified ARCA-capped mRNAs (cmRNAs) encoding Interleukin-1 receptor antagonist (IL1RA) and Platelet-Derived Growth Factor-BB (PDGF-BB) using injectable nanoparticle (NP) carriers. In vitro experiments demonstrate successful cmRNA delivery and translation, resulting in increased tendon cell proliferation, migration, and anti-inflammatory responses. In vivo, cmRNA treatment notably enhances tendon repair in a rat patellar tendon defect model, by reducing pro-inflammatory cytokines and fibrotic markers while enhancing repair tissue structure. These findings suggest that NP-based cmRNA delivery represents a promising therapeutic strategy for improving tendon healing, offering better outcomes over existing treatments by targeting both inflammatory and regenerative pathways. STATEMENT OF SIGNIFICANCE: In this study, we investigate an mRNA-based therapeutic approach aimed at enhancing tendon healing in a small animal model. Utilizing bioreducible poly(amidoamine)-based polymeric nanoparticles (PAA PNPs) for the delivery of cmRNAs encoding Interleukin-1 receptor antagonist (IL1RA) and Platelet-Derived Growth Factor-BB (PDGF-BB), we demonstrate effective delivery and protein translation in vitro and ex vivo, resulting in enhanced tendon cell proliferation, migration, and robust anti-inflammatory responses. By combining these therapeutic cmRNAs, we show improved tendon repair in vivo, with accelerated tissue regeneration, better collagen fiber organization, and signs of reduced fibrotic scarring. These findings highlight the potential of nanoparticle-mediated cmRNA delivery targeting two distinct pathways to improve tendon healing, offering a promising alternative to current treatments that often yield suboptimal results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesRNA, MessengerBecaplerminInterleukin 1 Receptor Antagonist ProteinWound HealingTendon InjuriesTendonsAnimalsRatsRats, Sprague-DawleyMaleInjections

Stichwörter der Autor:innen

Chemically modified mRNA (cmRNA)Drug delivery systemsIL1RAPDGF-BBPoly(amidoamine) nanoparticlesTendinopathyTendon healing

Substanzen

RNA, MessengerBecaplerminInterleukin 1 Receptor Antagonist Protein

Autor:innen und Institutionen

  • Institute of Tendon and Bone Regeneration, Paracelsus Medical University, 5020 Salzburg, Austria; Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria; Austrian Cluster for Tissu…
  • Institute of Tendon and Bone Regeneration, Paracelsus Medical University, 5020 Salzburg, Austria; Austrian Cluster for Tissue Regeneration, 1200 Vienna, Austria.
  • 20Med Therapeutics B.V., 2333BD Leiden, the Netherlands.
  • ETHRIS GmbH, 82152 Planegg, Germany.
  • Institute of Tendon and Bone Regeneration, Paracelsus Medical University, 5020 Salzburg, Austria; Austrian Cluster for Tissue Regeneration, 1200 Vienna, Austria. Electronic address: andreas.traweger@pmu.ac.at.

Förderung

  • Eurostars

Zitieren

APA

Faustini, B., Lettner, T., Wagner, A., Tempfer, H., Cesur, N. P., Lehner, C., Brouwer, C., Roelofs, K., Mykhailyk, O., Plank, C., Rip, J., Gehwolf, R., & Traweger, A. (2025). Improved tendon repair with optimized chemically modified mRNAs: Combined delivery of Pdgf-BB and IL-1Ra using injectable nanoparticles. Acta Biomaterialia, 195, 451-466. https://doi.org/10.1016/j.actbio.2025.02.025

Vancouver

Faustini B, Lettner T, Wagner A, Tempfer H, Cesur NP, Lehner C, et al. Improved tendon repair with optimized chemically modified mRNAs: Combined delivery of Pdgf-BB and IL-1Ra using injectable nanoparticles. Acta Biomaterialia. 2025;195:451-466. doi:10.1016/j.actbio.2025.02.025

BibTeX
@article{Faustini2025,
  author = {Faustini, Bettina and Lettner, Thomas and Wagner, Andrea and Tempfer, Herbert and Cesur, Nevra Pelin and Lehner, Christine and Brouwer, Chantal and Roelofs, Karin and Mykhailyk, Olga and Plank, Christian and Rip, Jaap and Gehwolf, Renate and Traweger, Andreas},
  title = {Improved tendon repair with optimized chemically modified mRNAs: Combined delivery of Pdgf-BB and IL-1Ra using injectable nanoparticles},
  journal = {Acta Biomaterialia},
  year = {2025},
  volume = {195},
  pages = {451--466},
  doi = {10.1016/j.actbio.2025.02.025}
}
Kostenlos starten →